96799-04-1

Basic information

• Product Name: 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE
• Synonyms: 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE;3-Amino-5-(3-methoxyphenyl)-1H-pyrazole;1H-Pyrazol-3-amine, 5-(3-methoxyphenyl)-;3-(3-methoxyphenyl)-1H-pyrazol-5-amine(SALTDATA: HCl);3-(3-methoxyphenyl)-1H-pyrazol-5-amine 1HCl;[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]amine
• CAS NO: 96799-04-1
• Molecular Formula: C₁₀H₁₁N₃O
• Molecular Weight: 189.21
• Mol File: 96799-04-1.mol

Chemical Properties

• Boiling Point: 456.7 °C at 760 mmHg
• Flash Point: 230 °C
• Appearance: /
• Density: 1.24 g/cm³
• Vapor Pressure: 1.58E-08mmHg at 25°C
• Refractive Index: 1.63
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.54±0.10(Predicted)
• CAS DataBase Reference: 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(96799-04-1)
• EPA Substance Registry System: 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(96799-04-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 96799-04-1(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE is used as a functional group for designing bioactive molecules due to its potential to exhibit biological activities such as anti-inflammatory, analgesic, or antimicrobial properties.
Used in Drug Development:
In the pharmaceutical industry, 5-(3-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE is utilized as a lead compound for drug discovery efforts, leveraging its structural features to improve the solubility and pharmacokinetic profiles of new drug candidates.

InChI:InChI=1/C10H11N3O/c1-14-8-4-2-3-7(5-8)9-6-10(11)13-12-9/h2-6H,1H3,(H3,11,12,13)

Upstream product

• 10259-22-0 ethyl 3-methoxybenzoate 
• 21667-60-7 3-methoxybenzoylacetonitrile 
• 5368-81-0 methyl 3-methoxybenzoate 
• 3672-47-7 3-oxo-3-(4'-methoxyphenyl)propanenitrile 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 96799-06-3 2-(4-Fluoro-phenyl)-7-(3-methoxy-phenyl)-4-(4-trifluoromethyl-phenyl)-pyrazolo[1,5-a][1,3,5]triazine 
• 96799-17-6 7-(3-Methoxy-phenyl)-2-phenyl-4-(4-trifluoromethyl-phenyl)-pyrazolo[1,5-a][1,3,5]triazine 
• 1040724-95-5 4-bromo-N-[5-(3-methoxy-phenyl)-1H-pyrazol-3-yl]-butyramide 
• 1040724-95-5 C₁₄H₁₆BrN₃O₂ 

Relevant articles and documents

Polysubstituted heterocyclic derivative, preparation method thereof and application of polysubstituted heterocyclic derivative in medicine

The invention provides a polysubstituted heterocyclic derivative, a preparation method thereof and application of the polysubstituted heterocyclic derivative in medicine, and belongs to the technical field of medicinal chemistry. The polysubstituted heterocyclic derivative is a compound shown in a general formula I or II, a pharmaceutically acceptable salt or a solvate of the compound, and the compound can inhibit mRNA demethylase on the protease level and is used for treating diseases related to mRNA demethylase functions.

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

3,5-Diaryl-1H-pyrazolo[3,4-b]pyridines as potent tubulin polymerization inhibitors: Rational design, synthesis and biological evaluation

A series of novel 3,5-diaryl-1H-pyrazolo[3,4-b]pyridines as tubulin polymerization inhibitors targeting the colchicine site were designed via ring tethering strategy, which was supported by conformational analysis. The general, chemically unstable and rot

Synthesis of pyrazolopyrimidinones using a “one-pot” approach under microwave irradiation

A simple one-pot method for the microwave-assisted synthesis of substituted pyrazolo[1,5-a]pyrimidinones, a core scaffold in many bioactive and pharmaceutically relevant compounds, has been established. A variety of substituents was tolerated at the 2 and 5 positions, including functionalized aryls, heterocycles, and alkyl groups.

Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H- pyrazol-3-yl] amide (SEN15924, WAY-361789)

Alpha-7 nicotinic acetylcholine receptors (α7 nAChR) are implicated in the modulation of many cognitive functions such as attention, working memory, and episodic memory. For this reason, α7 nAChR agonists represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort, around our previously reported chemical series, permitted the discovery of a novel class of α7 nAChR agonists with improved selectivity, in particular against the α3 receptor subtype and better ADME profile. The exploration of this series led to the identification of 5-(4-acetyl[1,4] diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (25, SEN15924, WAY-361789), a novel, full agonist of the α7 nAChR that was evaluated in vitro and in vivo. Compound 25 proved to be potent and selective, and it demonstrated a fair pharmacokinetic profile accompanied by efficacy in rodent behavioral cognition models (novel object recognition and auditory sensory gating).

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.

Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure-activity relationships of phenylpiperazine derivatives

A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by 1-phenylpiperazine, resulting in novel urea derivative 3f. Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor.